1. Home
  2. Labeler Index
  3. Lupin Limited
  4. 57297-117
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Levetiracetam NDC 57297-117 by Lupin Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Molecular Structure-Levetiracetam - 0ec567ac 9f44 4b97 92af 1bb615d146fb 01

Molecular Structure-Levetiracetam - 0ec567ac 9f44 4b97 92af 1bb615d146fb 01

Figure 1 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 02

Figure 1 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 02

The text represents a mixture of percentages and numerical values along with the comparison of different groups with the placebo group. However, it lacks context and meaning to derive a clear description to summarize.*

Figure 2 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 03

Figure 2 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 03

This appears to be a table or data analysis report. It provides percentages and dosage information for two types of levitiracetam medication (immediate-release and placebo) and includes a note about a statistically significant finding. There is not enough context to determine the purpose or relevance of this information.*

Figure 3 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 04

Figure 3 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 04

This is a chart showing the percentage of patients experiencing a particular outcome. The chart includes two groups, a placebo group (N=104) and a group taking 3000 mg/day of immediate-release levetiracetam (N=180). There are data points at 14.4% and 39.4%, with a note that the 39.4% data point is statistically significant versus placebo. No further information is available.*

Figure 4 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 05

Figure 4 - 0ec567ac 9f44 4b97 92af 1bb615d146fb 05

This appears to be a graph or chart representing the efficacy of levetiracetam versus placebo in treating patients. The percentages listed may indicate levels of improvement or response in patients. The number of patients in each group is also provided. Additionally, there is a note indicating that the difference between the two groups was statistically significant.*

Conatiner Label 500 mg-Bottle of 60 Tablets - 0ec567ac 9f44 4b97 92af 1bb615d146fb 06

Conatiner Label 500 mg-Bottle of 60 Tablets - 0ec567ac 9f44 4b97 92af 1bb615d146fb 06

This is a medication description for extended-release tablets of levetiracetam, a drug used for treating epilepsy, with the dosage specified in the prescribing information. The tablets should be stored at a temperature between 15°C to 30°C. It also includes information for pharmacists and the manufacturer based in Baltimore, Maryland. The text ends with details of a patent and a code for the tablets.*

Conatiner Label 750 mg-Bottle of 60 Tablets - 0ec567ac 9f44 4b97 92af 1bb615d146fb 07

Conatiner Label 750 mg-Bottle of 60 Tablets - 0ec567ac 9f44 4b97 92af 1bb615d146fb 07

This is a medication information sheet for Levetiracetam USP 750 mg extended-release tablets. The recommended dosage is not provided in the text, but details on proper storage and dispensing are given. The tablets should be stored at room temperature and dispensed in a light-resistant container with a child-resistant closure. The manufacturer is Lupin Pharmaceuticals, Inc. This information sheet is directed at pharmacists and is accompanied by educational materials.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.